Helix Biopharma Corp. (HBPCF) 1.5061 $HBPCF
Helix BioPharma Corp. Appoints New Independent Chair of the Board
Marketwire Canada - Mon Jul 21, 8:15AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the appointment of Mr. Yvon Bastien as the new Chair of the board effective July 17, 2014. Mr. Bastien has served as an independent director of the Company since December 2013 and remains the Chair of the board's Governance & Compensation Committee. Mr. Robert Verhagen has served as Interim Chair since December 2013 and remains a Director of the Company and President and CEO.
Helix BioPharma Corp. Initiates Enrollment for Ninth Cohort in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47
Marketwire - Tue Jul 15, 7:32AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening for the ninth dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland ("LDOS002"
. This follows completion of the first treatment cycle in the three patients enrolled in the eighth dose level cohort, in which L-DOS47 therapy was well tolerated, as reviewed by the Trial Steering Committee.
Helix BioPharma Corp. Announces Completion of Private Placement
Marketwire - Fri Jul 11, 7:00AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has completed a private placement with net proceeds in excess of CAD5.4 million, after fees and expenses associated with the placement.
Helix BioPharma Corp. Announces the Receipt of Subscription Agreements for a Net CAD5.4 Million Private Placement
Marketwire Canada - Mon Jul 07, 6:25AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has received private placement subscription agreements for common shares and warrants for aggregate net proceeds in excess of CAD5.4 million after expected expenses. Proceeds of the placement will be used for working capital to support the Company's expanding clinical trial initiatives.
Global Human Papillomavirus Infections Pipeline Analysis 2014
M2 - Thu Jun 19, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r42gfc/human) has announced the addition of the "Human Papillomavirus Infections Pipeline Analysis" report to their offering. Currently there is significant amount of research being undertaken to study the process of HPV infection causing precancerous changes in normal cells. Also, methods to prevent and manage this situation are also being analyzed. A majority of these studies were previously focusing on cervical cells in women. But in recent years, the realm of research has been extended to other tissues also in which HPV may cause cancer, such as the oropharynx and anus. Also, many organizations are analyzing the use of second-generation preventive vaccines along with therapeutic HPV vaccines, which could possibly prevent the development of cancer among women previously infected with HPV. Such an ideal vaccine strategy would combine a preventive and therapeutic vaccine, which would help in a major way. The mechanism of the HPV vaccines is similar to the other immunizations which help in protecting against viral infections. It has been observed and analyzed that the unique surface components of HPV have the capability to create an antibody response which could possibly protect the human body against infection. These components could thus be used as a basis of the vaccine. There are only 2 HPV vaccines which are currently marketed across the globe. Both these vaccines are prepared using the recombinant technology, which is taken from purified L1 structural proteins which self assemble to form HPV type-specific empty shells or virus-like particles (VLPs). Since there are no therapeutic HPV vaccines available at present which have proved their efficiency in the clinical trials, there is still a lot of work which is required in this field, thus opening a large window of opportunities. There have been some technological advancements in the past 4-5 years. The future is also likely to continue to witness similar technological and medical success in terms of new drugs and efficient vaccines, with the help of adequate funding. Certain developments like a new treatment to reduce transmissibility in drug users and new efforts to strengthen the immune system have the potential to develop further and provide better healthcare services to the patients in the future. Thus, there needs to be more focus being given to increasing the knowledge and awareness about HPV infections and the ways and methods to treat it, either through drugs or through vaccines. Human Papillomavirus Infections Vaccine Pipeline Analysis - Report Highlights: - Human Papillomavirus Vaccine Market Overview - Marketed Drug Profiles & Patent Analysis - Clinical Trial Insight by Phase & Country - Drug Clinical Development Phase: 47 - Suspended & Discontinued Drug Profiles: 46 - Competitive Landscape Companies Mentioned - Advanced Viral Research - BioSphings, - Biogen Idec, - EyeGene, - Helix BioPharma, - Inviragen, - MedImmune, - Merck & Co, - Valeant Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/r42gfc/human
Helix BioPharma Corp. Announces Fiscal Q3 2014 Results
Marketwire - Thu Jun 12, 8:02AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced financial results for the three and nine-month periods ended April 30, 2014 and 2013.
Helix BioPharma Corp. Announces Appointment of New Director and Observer to the Board of Directors
Marketwire Canada - Tue Mar 11, 4:00PM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced the appointment of Mr. Sylwester Cacek to the board of directors. Mr. Cacek's appointment was effective March 7, 2014.
Helix BioPharma Corp. Initiates Enrollment for Seventh Cohort in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47
Marketwire Canada - Tue Feb 18, 4:42PM CST
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening for the seventh dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland. This follows completion of the first treatment cycle of the three patients enrolled in the sixth dose level cohort, in which L-DOS47 therapy was well tolerated as reviewed by the Trial Steering Committee.
Genital Warts (Condylomata Acuminata) - Pipeline Review, H2 2013 Report
M2 - Mon Jan 27, 2:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/76wqwr/genital_warts) has announced the addition of the "Genital Warts (Condylomata Acuminata) - Pipeline Review, H2 2013" report to their offering. 'Genital Warts (Condylomata Acuminata) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Genital Warts (Condylomata Acuminata), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Genital Warts (Condylomata Acuminata). Scope - A snapshot of the global therapeutic scenario for Genital Warts (Condylomata Acuminata). - A review of the Genital Warts (Condylomata Acuminata) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Genital Warts (Condylomata Acuminata) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Genital Warts (Condylomata Acuminata) Overview Therapeutics Development Pipeline Products for Genital Warts (Condylomata Acuminata) - Overview Pipeline Products for Genital Warts (Condylomata Acuminata) - Comparative Analysis Genital Warts (Condylomata Acuminata) - Therapeutics under Development by Companies Genital Warts (Condylomata Acuminata) - Pipeline Products Glance Clinical Stage Products Early Stage Products Genital Warts (Condylomata Acuminata) - Products under Development by Companies Genital Warts (Condylomata Acuminata) - Companies Involved in Therapeutics Development Genital Warts (Condylomata Acuminata) - Therapeutics Assessment Assessment by Monotherapy Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Companies Mentioned Helix BioPharma Corp. Inovio Pharmaceuticals, Inc. NanoViricides, Inc. G&E Herbal Biotechnology Co., Ltd. Anaconda Pharma Foamix Ltd. Telormedix SA Genetic Immunity, Inc Xiamen Amoytop Biotech Co., Ltd. For more information visit http://www.researchandmarkets.com/research/76...ital_warts About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Director of Helix BioPharma Corp. Acquires a Further 1,000,000 Common Shares
Marketwire Canada - Fri Jan 10, 9:37AM CST
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company dedicated to developing drugs for prevention and treatment of cancer, today announced that it has been advised by Dr. Marek Orlowski, a member of the board of directors of Helix and Chairman of the Supervisory Board of Helix Polska, that he has purchased 1,000,000 previously issued and outstanding shares of Helix for a total purchase price of approximately CAD$1.72 million since December 30, 2013.
Helix BioPharma Corp. Appoints New Independent Chair of the Board
Marketwire Canada - Mon Jul 21, 8:15AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the appointment of Mr. Yvon Bastien as the new Chair of the board effective July 17, 2014. Mr. Bastien has served as an independent director of the Company since December 2013 and remains the Chair of the board's Governance & Compensation Committee. Mr. Robert Verhagen has served as Interim Chair since December 2013 and remains a Director of the Company and President and CEO.
Helix BioPharma Corp. Initiates Enrollment for Ninth Cohort in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47
Marketwire - Tue Jul 15, 7:32AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening for the ninth dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland ("LDOS002"
. This follows completion of the first treatment cycle in the three patients enrolled in the eighth dose level cohort, in which L-DOS47 therapy was well tolerated, as reviewed by the Trial Steering Committee. Helix BioPharma Corp. Announces Completion of Private Placement
Marketwire - Fri Jul 11, 7:00AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has completed a private placement with net proceeds in excess of CAD5.4 million, after fees and expenses associated with the placement.
Helix BioPharma Corp. Announces the Receipt of Subscription Agreements for a Net CAD5.4 Million Private Placement
Marketwire Canada - Mon Jul 07, 6:25AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has received private placement subscription agreements for common shares and warrants for aggregate net proceeds in excess of CAD5.4 million after expected expenses. Proceeds of the placement will be used for working capital to support the Company's expanding clinical trial initiatives.
Global Human Papillomavirus Infections Pipeline Analysis 2014
M2 - Thu Jun 19, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r42gfc/human) has announced the addition of the "Human Papillomavirus Infections Pipeline Analysis" report to their offering. Currently there is significant amount of research being undertaken to study the process of HPV infection causing precancerous changes in normal cells. Also, methods to prevent and manage this situation are also being analyzed. A majority of these studies were previously focusing on cervical cells in women. But in recent years, the realm of research has been extended to other tissues also in which HPV may cause cancer, such as the oropharynx and anus. Also, many organizations are analyzing the use of second-generation preventive vaccines along with therapeutic HPV vaccines, which could possibly prevent the development of cancer among women previously infected with HPV. Such an ideal vaccine strategy would combine a preventive and therapeutic vaccine, which would help in a major way. The mechanism of the HPV vaccines is similar to the other immunizations which help in protecting against viral infections. It has been observed and analyzed that the unique surface components of HPV have the capability to create an antibody response which could possibly protect the human body against infection. These components could thus be used as a basis of the vaccine. There are only 2 HPV vaccines which are currently marketed across the globe. Both these vaccines are prepared using the recombinant technology, which is taken from purified L1 structural proteins which self assemble to form HPV type-specific empty shells or virus-like particles (VLPs). Since there are no therapeutic HPV vaccines available at present which have proved their efficiency in the clinical trials, there is still a lot of work which is required in this field, thus opening a large window of opportunities. There have been some technological advancements in the past 4-5 years. The future is also likely to continue to witness similar technological and medical success in terms of new drugs and efficient vaccines, with the help of adequate funding. Certain developments like a new treatment to reduce transmissibility in drug users and new efforts to strengthen the immune system have the potential to develop further and provide better healthcare services to the patients in the future. Thus, there needs to be more focus being given to increasing the knowledge and awareness about HPV infections and the ways and methods to treat it, either through drugs or through vaccines. Human Papillomavirus Infections Vaccine Pipeline Analysis - Report Highlights: - Human Papillomavirus Vaccine Market Overview - Marketed Drug Profiles & Patent Analysis - Clinical Trial Insight by Phase & Country - Drug Clinical Development Phase: 47 - Suspended & Discontinued Drug Profiles: 46 - Competitive Landscape Companies Mentioned - Advanced Viral Research - BioSphings, - Biogen Idec, - EyeGene, - Helix BioPharma, - Inviragen, - MedImmune, - Merck & Co, - Valeant Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/r42gfc/human
Helix BioPharma Corp. Announces Fiscal Q3 2014 Results
Marketwire - Thu Jun 12, 8:02AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced financial results for the three and nine-month periods ended April 30, 2014 and 2013.
Helix BioPharma Corp. Announces Appointment of New Director and Observer to the Board of Directors
Marketwire Canada - Tue Mar 11, 4:00PM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced the appointment of Mr. Sylwester Cacek to the board of directors. Mr. Cacek's appointment was effective March 7, 2014.
Helix BioPharma Corp. Initiates Enrollment for Seventh Cohort in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47
Marketwire Canada - Tue Feb 18, 4:42PM CST
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening for the seventh dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland. This follows completion of the first treatment cycle of the three patients enrolled in the sixth dose level cohort, in which L-DOS47 therapy was well tolerated as reviewed by the Trial Steering Committee.
Genital Warts (Condylomata Acuminata) - Pipeline Review, H2 2013 Report
M2 - Mon Jan 27, 2:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/76wqwr/genital_warts) has announced the addition of the "Genital Warts (Condylomata Acuminata) - Pipeline Review, H2 2013" report to their offering. 'Genital Warts (Condylomata Acuminata) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Genital Warts (Condylomata Acuminata), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Genital Warts (Condylomata Acuminata). Scope - A snapshot of the global therapeutic scenario for Genital Warts (Condylomata Acuminata). - A review of the Genital Warts (Condylomata Acuminata) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Genital Warts (Condylomata Acuminata) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Genital Warts (Condylomata Acuminata) Overview Therapeutics Development Pipeline Products for Genital Warts (Condylomata Acuminata) - Overview Pipeline Products for Genital Warts (Condylomata Acuminata) - Comparative Analysis Genital Warts (Condylomata Acuminata) - Therapeutics under Development by Companies Genital Warts (Condylomata Acuminata) - Pipeline Products Glance Clinical Stage Products Early Stage Products Genital Warts (Condylomata Acuminata) - Products under Development by Companies Genital Warts (Condylomata Acuminata) - Companies Involved in Therapeutics Development Genital Warts (Condylomata Acuminata) - Therapeutics Assessment Assessment by Monotherapy Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Companies Mentioned Helix BioPharma Corp. Inovio Pharmaceuticals, Inc. NanoViricides, Inc. G&E Herbal Biotechnology Co., Ltd. Anaconda Pharma Foamix Ltd. Telormedix SA Genetic Immunity, Inc Xiamen Amoytop Biotech Co., Ltd. For more information visit http://www.researchandmarkets.com/research/76...ital_warts About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Director of Helix BioPharma Corp. Acquires a Further 1,000,000 Common Shares
Marketwire Canada - Fri Jan 10, 9:37AM CST
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company dedicated to developing drugs for prevention and treatment of cancer, today announced that it has been advised by Dr. Marek Orlowski, a member of the board of directors of Helix and Chairman of the Supervisory Board of Helix Polska, that he has purchased 1,000,000 previously issued and outstanding shares of Helix for a total purchase price of approximately CAD$1.72 million since December 30, 2013.
